| Patent Number |
Title Of Patent |
Date Issued |
| 5892112 |
Process for preparing synthetic matrix metalloprotease inhibitors |
April 6, 1999 |
| Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds |
| 5874411 |
Oligosaccharide glycosides having mammalian immunosuppresive and tolerogenic properties |
February 23, 1999 |
| Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a |
| 5849709 |
Saccharopeptides and derivatives thereof |
December 15, 1998 |
| Saccharopeptides and methods of using the novel saccharopeptides are described having the following structural formula I:wherein W is independently one or more saccharide(s); Y is independently --CO--NH-- or --NH--CO--; and m is an integer greater than or equal to one; or structural form |
| 5837690 |
Derivatives of triterpenoid acids and uses thereof. |
November 17, 1998 |
| Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer a |
| 5837689 |
Sialyl lewis-x mimetics containing naphthyl backbones |
November 17, 1998 |
| Compounds that possess selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or their mimics are separated by a linker that permits bind |
| 5808021 |
Method for controlling O-desulfation of heparin |
September 15, 1998 |
| Methods of making and using, as prophylactics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation |
| 5795875 |
Therapeutic methods of using O-desulfated heparin derivatives |
August 18, 1998 |
| Compositions and methods of making selectively O-desulfated heparin compositions, preferably 6-O-desulfated heparin compositions, wherein the methods permit regulating the degree of 6-O-desulfation. The compositions are useful for treating various diseases, including cancer, angiogenesis |
| 5789385 |
Sialyl Lewis.sup.x mimetics containing phenyl backbones |
August 4, 1998 |
| Compounds that possess selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or their mimics are separated by a linker that permits bind |
| 5773438 |
Synthetic matrix metalloprotease inhibitors and use thereof |
June 30, 1998 |
| Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds |
| 5763582 |
Derivatives of triterpenoid acids and uses thereof |
June 9, 1998 |
| Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer a |
| 5750508 |
Sialic acid/fucose based medicaments |
May 12, 1998 |
| Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups |
| 5739115 |
Sulfated maltooligosaccharides with heparin-like properties |
April 14, 1998 |
| A novel class of highly sulfated maltooligosaccharide having heparin-like activity is described, as well as methods for using these oligosaccharides to treat certain diseases including cancer, and retinopathies. |
| 5728685 |
Methods of treating inflammation using cell adhesion inhibitors |
March 17, 1998 |
| Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R.sup.1 is independently H or |
| 5696100 |
Method for controlling O-desulfation of heparin and compositions produced thereby |
December 9, 1997 |
| Methods of making and using, as prophylactics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation |
| 5695738 |
Steroidal C-glycosides |
December 9, 1997 |
| Compositions of sterodial glycosides are described wherein the glycoside is linked directly, or indirectly to a desired steroidal compound via a carbon, or similar stable linkage, and methods of using the compositions to treat patients by binding to and/or blocking cellular receptors for |
| 5688922 |
Substituted fucopyranosides |
November 18, 1997 |
| 2-Chloromethyl-3-(tri-O-benzyl-.alpha.-L-C-fucopyranoside)-1-propene and methods of making the same are described. Methods of combining this substituted fucopyranose with triterpenoid acid also are described. |
| 5679644 |
Methods of treating diseases using triterpenoid acid derivatives |
October 21, 1997 |
| Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer a |
| 5679321 |
Sialic acid/fucose based medicaments |
October 21, 1997 |
| Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups |
| 5660992 |
Sialic acid/fucose based assay reagents and assay methods |
August 26, 1997 |
| Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups |
| 5658880 |
Sialic acid/fucose based medicaments |
August 19, 1997 |
| Compounds that exhibit selectin binding activity are described and have the following structural formula: ##STR1## where W is selected from a group including structures a-d below ##STR2## wherein p is an integer of from 0-2, q is an integer of from 0-3, and r is an integer of |
| 5654412 |
Processes for the synthesis of sialyl Lewis.sup.x compounds |
August 5, 1997 |
| Disclosed are processes for the chemical synthesis of sialyl Lewis.sup.x -Y compounds where Y is --OH, --NHR, --SH, --SR or --OR, and R is an aglycon of at least one carbon atom. |
| 5654282 |
Selectin binding glycopeptides |
August 5, 1997 |
| Glyco-amino acids and glycopeptides having three-dimensionally stable configurations are described. These glyco-amino acids and glycopeptides have glycoside functional groups, such as fucose and analogues and derivatives thereof, covalently bound to an amino acid or peptide having a |
| 5648344 |
Methods of treating inflammation using selection binding compounds |
July 15, 1997 |
| Ligands that bind to human selectin receptors are disclosed. The ligands are formulated with excipient carriers to form compositions which are administered to treated condition such as inflammation. The ligands have the structural formula III ##STR1## or molecules which have hydr |
| 5643884 |
Lupane triterpenoid derivatives |
July 1, 1997 |
| This invention relates generally to the field of medicinal chemistry, and more specifically to derivatives of a subclass of triterpenoid acids that have multi-medicament properties, that is derivatives of the lupane, betulinic acid, formulations containing such, and their use to prevent |
| 5624909 |
Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (e-selectin) a |
April 29, 1997 |
| Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). T |
| 5591835 |
Substituted lactose derivatives |
January 7, 1997 |
| Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R.sup.1 is independently H or |
| 5583121 |
Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related sho |
December 10, 1996 |
| A method of treating hypovolemic shock and related shock syndromes by the administration of substantially non-anticoagulant heparinoids without the hemorrhaging problems generally associated with heparin; such syndromes include degradation of the microvascular structure, immune and g |
| 5567683 |
Substituted lactose and lactosamine derivatives as cell adhesion inhibitors |
October 22, 1996 |
| Simple lactose or lactosamine related compounds which behave as ligands for the ELAM-1 and related receptors are described. These compounds are useful in the treatment of conditions characterized by excess inflammation. These compounds are of the formula ##STR1## wherein each R.s |
| 5527890 |
Derivatives of triterpenoid acids and uses thereof |
June 18, 1996 |
| Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer a |
| 5519008 |
Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) a |
May 21, 1996 |
| Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). T |
| 5508387 |
Selectin binding glycopeptides |
April 16, 1996 |
| Glyco-amino acids or glycopeptides that have three-dimensionally stable configuration for the presentation of functional groups, fucose, or an analogue or derivative thereof, covalently linked to an amino acid or peptide with a free carboxylic acid group, that facilitate binding between |
| 5470842 |
Carbohydrate-based anti-inflammatory agents |
November 28, 1995 |
| Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of ( |
| 5440015 |
Selectin peptide medicaments for treating disease |
August 8, 1995 |
| Peptides are described and methods of using the peptides to treat or prevent disease which peptides are described by the formula:wherein X is an aromatic amino acid, and n is 1, 2, or 3; X' is either a non-polar or polar uncharged amino acid, and n' is 1, 2, or 3; X" is a basic amino aci |
| 5428025 |
Method of treating inflammation by blocking ELAM-1 receptor sites |
June 27, 1995 |
| Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of ( |
| 5412123 |
Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the imm |
May 2, 1995 |
| Derivatives of anthraquinone and anthracene are synthesized and formulated into pharmaceutical formulations. When the formulations are administered the derivatives act as ligands binding to an interrupting the biological chain of events associated with selectin receptors in the human bod |
| 5326752 |
Substituted lactose and lactosamine derivatives as cell adhesion inhibitors |
July 5, 1994 |
| The compounds are of the formula ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, lower alkyl (1-4C), alkylaryl or one or more additional saccharide residues; R.sup.3 and R.sup.4 are independently H, alkyl (1-6C), aryl or R.sup.3 and R.sup.4, |
| 5296471 |
Method for controlling o-desulfation of heparin and compositions produced thereby |
March 22, 1994 |
| Methods of making and using, as prophylatics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to |
| 5280016 |
Non-anticoagulant heparin derivatives |
January 18, 1994 |
| A non-anticoagulant (NAC) form of heparin which shows antiproliferative activity with respect to smooth muscle cells is useful in the prevention of restenosis and other conditions benefited by antiproliferative activity with respect to smooth muscle cells. This NAC form of heparin is pre |
| 5250519 |
Non-anticoagulant heparin derivatives |
October 5, 1993 |
| A non-anticoagulant (NAC) form of heparin which shows antiproliferative activity with respect to smooth muscle cells is useful in the prevention of restenosis and other conditions benefited by antiproliferative activity with respect to smooth muscle cells. This NAC form of heparin is pre |
| 5239078 |
Matrix metalloprotease inhibitors |
August 24, 1993 |
| Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;R.sup.3 is H or alkyl (1-4C);R.sup.4 is fused or conjugated unsubs |
| 5211937 |
Method of determining a site of inflammation utilizing ELAM-1 ligands |
May 18, 1993 |
| Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of ( |
| 5211936 |
Method of determining a cite of inflammation utilizing elam-1 ligands site |
May 18, 1993 |
| Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of ( |
| 5145956 |
Method for separation of anionic oligosaccharides |
September 8, 1992 |
| Separation of anionic oligosaccharides on a preparative scale with high resolution can be achieved by anionic exchange chromatography using PEI-derivatized supports. |
| 5143712 |
Method of determining a site of inflammation utilizing elam-1 ligands |
September 1, 1992 |
| Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of ( |
| 5035786 |
Fluorescent tag for sugar electrophoresis |
July 30, 1991 |
| A method of separating mixtures of saccharides into distinct detectable groups is disclosed. The method comprises modifying 1-amino-4-naphthalene sulfonic acid (ANSA) with a light-sensitive azido-group and binding the modified ANSA to saccharides to form ANSA/saccharide conjugates. The |
| 5019231 |
Electro-blotting of electrophoretically resolved fluroescent-labeled saccharides and detection o |
May 28, 1991 |
| Saccharide in mixtures are separated into groups or individual saccharides and tested for their affinity for particular proteins. The method of the invention is carried out by conjugating saccharides in a mixture with 4-amino-1-naphthalene sulfonic acid (ANSA) to form conjugates. The |
